Delta sleep-inducing peptide (DSIP), also known as emideltide, has been linked to several adverse effects in limited human studies. Reported symptoms included headache, nausea, dizziness, sweating, temporary agitation, and low blood pressure. However, the overall safety profile of DSIP remains unclear. Most human studies were small, short-term, and conducted decades ago. They primarily used DSIP administered intravenously under medical or research supervision. This differs significantly from subcutaneous injections and nasal sprays, which are currently frequently discussed or sold online.
Therefore, the main safety issue is not a long list of confirmed side effects of DSIP. A greater limitation is the lack of sufficient data to determine how often adverse events occur, how severe they might be, whether they are dose-dependent, and what the consequences of repeated or long-term exposure might be.
Some historical studies on insomnia indicated a small number of significant side effects or none at all. However, they included very small groups of participants and short treatment periods. In a larger, uncontrolled study involving individuals undergoing alcohol or opioid withdrawal, several mild reactions and cases of low blood pressure were reported. Some of these symptoms could also have resulted from the withdrawal syndrome itself [1–4].
Product quality represents an additional source of uncertainty. Results regarding carefully prepared DSIP administered intravenously in studies from several decades ago cannot confirm the safety of a modern product sold online as „research grade”, a subcutaneous preparation, or a DSIP nasal spray.
In a 2026 assessment, the U.S. Food and Drug Administration (FDA) concluded that substances related to emideltide have not been sufficiently characterized for human use. The FDA highlighted peptide impurities, aggregation, endotoxin testing, and the potential for immune reactions. The agency also proposed that emideltide as a free base and emideltide acetate not be included on the Section 503A bulk drug substances list [1,5].
What side effects of DSIP have been reported?
Most of the published information regarding the side effects of DSIP comes from historical studies using intravenous administration. Much less is known about the intranasal and subcutaneous routes, which are now frequently discussed.
A 2026 FDA review identified human studies in which a total of 209 participants were administered emideltide intravenously in amounts ranging from 25 to 150 nmol/kg. Treatment periods ranged from one to 15 days. Importantly, the FDA found no clinical safety data regarding the proposed subcutaneous route [1].
One of the important sources of information on adverse events was an uncontrolled study on withdrawal syndrome.
In this study, 107 hospitalized patients undergoing alcohol or opioid withdrawal received DSIP intravenously. In the original publication, DSIP was described as generally well tolerated, with headaches reported in a small number of participants [4].
A more detailed FDA analysis revealed nine cases of mild and transient adverse events. These included:
- headache,
- nausea,
- sweating,
- dizziness.
Low blood pressure occurred in two participants at the start of the first infusion. Another participant experienced recurring episodes of general malaise, sweating, and nausea. Following the second administration, one case was described as „progressive hypotension” [1].
These results require cautious interpretation.
Alcohol and opioid withdrawal can in itself cause sweating, nausea, dizziness, anxiety, insomnia, and blood pressure instability. Because the study did not include a placebo group, it could not be definitively determined whether DSIP was the cause of each of these symptoms.
The FDA also noted that researchers reported solubility issues with certain DSIP vials. This creates additional uncertainty as to whether the formulation may have contributed to some of the observed reactions [1].
| Potential consequence or risk | Evidence | What is currently known |
|---|---|---|
| Headache | Reported in human studies during withdrawal | Transient headaches occurred, but the exact relationship with DSIP remains uncertain [1,4] |
| Nausea | Reported in human studies during withdrawal | They occurred in a small number of participants; the withdrawal syndrome may have also played a role [1] |
| Sweating | Reported in human studies | It occurred transiently in some participants [1] |
| Dizziness | Reported in human studies | They occurred in some participants, but the frequency and causal relationship remain uncertain [1] |
| Hypotension | Reported during intravenous treatment | Several cases were noted, including one described as progressive hypotension [1] |
| Short-term arousal | A small study on insomnia | Mild stimulation occurred in the first hour before the subsequent sleep-promoting effect [2] |
| Daytime sleepiness | Not observed in one very small study | In a study of six individuals, no daytime sleepiness was observed, but this does not rule out its possibility [2] |
| Fatigue | It has not been unequivocally confirmed | It appears in anecdotal reports, but controlled data is insufficient |
| Allergic or immunological reactions | Potential risk | The FDA pointed to immunogenicity concerns, but there is a lack of reliable data on frequency [1,5] |
| Infection or contamination | Risk related to the product and route of administration | Possible in the case of contaminated, non-sterile or improperly handled injection products |
Therefore, the available data does not allow DSIP to be classified as a „side-effect-free” substance.
At the same time, symptoms reported on forums or commercial websites should not automatically be presented as scientifically confirmed side effects of DSIP. Human observations, theoretical risks, product quality issues, and anecdotal accounts represent different levels of evidence.
How strong is the safety data on DSIP in humans?
Data on the safety of DSIP in humans are poor by modern standards.
Most studies were conducted in the 1980s and early 1990s. They typically involved a small number of participants and lasted for days rather than months or years.
Many studies have been designed primarily to assess sleep or withdrawal symptoms, rather than to monitor all potential adverse events in detail.
As a result, available studies do not adequately determine:
- long-term toxicity,
- reproductive safety and use during pregnancy,
- safety during breastfeeding,
- immunogenicity,
- cancer risk,
- chronic organ toxicity,
- drug interactions,
- risks in people with multiple comorbidities,
- child safety,
- security for the elderly or frail.
Some small studies on insomnia suggested relatively good short-term tolerance.
For example, Schneider-Helmert and Schoenenberger administered DSIP intravenously to six middle-aged individuals with chronic insomnia. They reported no daytime drowsiness or other significant side effects, although a mild stimulating effect was observed during the first hour [2].
However, six participants is definitely too small a group to determine the general safety profile.
Another controlled study on insomnia showed only limited clinical benefits [3]. This is also relevant when assessing safety, because tolerance alone does not imply a favorable benefit-risk ratio.
The FDA found no reports of adverse events regarding emideltide in the FDA Adverse Event Reporting System as of March 3, 2024, nor any relevant published case reports [1].
This does not mean that DSIP is safe.
A low number of reports may result from limited use, the sale of products outside the traditional healthcare system, inconsistent nomenclature, failure to recognize a causal relationship, or underreporting. The FDA also points out that traditional compounding pharmacies under Section 503A are not subject to the same adverse event reporting obligations as manufacturers of approved drugs [5].
Even less data exists for the routes of administration currently discussed on the internet.
The FDA found no clinical safety data regarding subcutaneous emideltide for the proposed use in compounded preparations [1]. Data regarding intranasal DSIP are also insufficient to establish local or systemic safety.
Historical intravenous studies cannot therefore automatically confirm the safety of intranasal DSIP or subcutaneous DSIP aerosol.
Long-term safety remains largely unknown.
Available studies do not determine whether repeated exposure to DSIP may cause antibody formation, changes in efficacy, immunological reactions, altered response to naturally occurring peptides, endocrinological effects, organ toxicity, or other delayed problems.
Can DSIP cause insomnia or worsened sleep?
DSIP may potentially be associated with worsening sleep in some situations, however, insomnia has not been established as a common side effect of DSIP.
The name „delta sleep-inducing peptide” might suggest that DSIP should immediately induce drowsiness. However, human studies indicate a much more complex picture.
In a small 1981 study involving six people with chronic insomnia, mild arousal was observed in the first hour after intravenous administration of DSIP. Sleep-promoting effects appeared mainly in the second hour [2].
Later studies were less convincing.
In a double-blind, crossover study from 1987, improvements in some sleep parameters were observed, but several differences compared to placebo did not reach statistical significance. The researchers considered the overall improvement to be of little clinical significance [3].
In a double-blind, 1992 study involving 16 people with chronic insomnia, poor results were also obtained. The researchers concluded that short-term use of DSIP is unlikely to provide significant therapeutic benefits [6].
These results show why reports such as „DSIP didn't help me sleep” or „DSIP made my sleep worse” should not be automatically interpreted as paradoxical toxicity.
Various explanations are possible, including an underlying sleep disorder, timing of administration, natural night-to-night variability, other medications or substances, expectancy effects, incorrect product content, product degradation, or a lack of significant DSIP activity.
A real adverse reaction is also possible, but current studies do not allow its frequency to be determined.
In some individuals undergoing opioid withdrawal, worsening sleep was also reported after the completion of DSIP treatment. The FDA noted a recurrence of anxiety and significant insomnia approximately 24 to 72 hours after the end of treatment in some participants who had previously experienced improvement [1].
This does not prove that DSIP caused rebound insomnia. Opioid withdrawal syndrome itself often causes variable severity of anxiety and sleep disturbances.
Persistent insomnia should be appropriately evaluated for recognized causes such as sleep apnea, restless legs syndrome, circadian rhythm disorders, anxiety or mood disorders, use of stimulants, alcohol, medications, pain, and other medical conditions.
Potential risks associated with nasal and injectable products
The safety of DSIP depends not only on the peptide itself.
Additional risks may be caused by the formulation, manufacturing quality, route of administration, sterility, storage conditions, and handling of the product.
Risks associated with DSIP for injection
Products intended for parenteral administration require rigorous quality control.
Key parameters include identity, concentration, sterility, bacterial endotoxin level, particulate matter, impurities, pH, osmolality, stability, and container closure integrity.
Terms such as „research grade,” „high purity,” or „HPLC tested” do not confirm that all of these requirements have been met.
For example, the percentage purity determined using the HPLC method does not in itself confirm sterility or the absence of bacterial endotoxins.
Injection also bypasses some of the body's natural protective barriers. A contaminated product or improper administration can lead to, among other things, local inflammation, redness, swelling, cellulitis, an abscess, or a serious systemic infection.
Endotoxins can also cause inflammatory reactions even when living bacteria are no longer present.
The FDA specifically highlighted concerns regarding emideltide aggregation, peptide-related impurities, endotoxin data in injectable products, and potential immunogenicity [1,5].
Immune reactions could theoretically include both local inflammation and systemic hypersensitivity or a decrease in biological activity. However, reliable data to determine the frequency of such reactions are lacking.
The historical tolerance of intravenous DSIP also does not confirm the safety of subcutaneously administered DSIP.
Intravenous infusion and subcutaneous administration lead to different exposure profiles and involve different tissues and formulation requirements.
Risks associated with intranasal DSIP
Human studies are insufficient to establish the safety, absorption, dosing consistency, or efficacy of DSIP nasal spray for insomnia.
Nasal preparations can potentially cause local issues such as irritation, dryness, burning, sneezing, nasal congestion, nosebleeds, or changes in smell. These are general potential risks associated with nasal formulations and should not be presented as confirmed side effects of DSIP with a specific frequency.
Absorption can also vary significantly.
Nasal congestion, inflammation, formulation properties, device performance, and the method of administration may affect the amount of material reaching the nasal mucosa and remaining on its surface.
Homemade or unvalidated nasal preparations introduce additional uncertainty regarding concentration, microbial contamination, pH, preservatives, and stability.
Therefore, the commercial DSIP nasal spray cannot be considered equivalent to intravenously administered DSIP in historical human studies.
Interactions of DSIP with alcohol, tirzepatide, and other substances
There is no reliable clinical database regarding DSIP interactions.
Interactions with alcohol, tirzepatide, sleeping pills, antidepressants, opioids, stimulants, and other peptides have not been adequately studied.
No data on interactions does not mean that a given connection is safe.
DSIP and alcohol
Historical studies involving individuals undergoing alcohol withdrawal should not be interpreted as evidence that DSIP can be safely combined with alcohol [4].
Treatment of withdrawal syndrome takes place after stopping or significantly reducing alcohol consumption and under medical supervision.
Alcohol alone can disrupt sleep, impair coordination, affect blood pressure, induce drowsiness, and subsequently contribute to sleep fragmentation.
The effect of DSIP on sleep, arousal, and blood pressure remains uncertain. Therefore, combining both substances could lead to unpredictable effects. However, this is a precaution resulting from the known and suspected properties of both substances, rather than a confirmed DSIP-alcohol interaction.
DSIP and tirzepatide
No clinical study has been published confirming a direct interaction between DSIP and tirzepatide.
Tirzepatide is an approved medication with known gastrointestinal side effects. It may also delay gastric emptying, potentially affecting the absorption of certain oral medications [7].
This mechanism does not automatically imply an interaction between tirzepatide and DSIP administered by injection or intranasally.
Tirzepatide may, however, cause nausea, vomiting, decreased food intake, and dizziness [7]. Since nausea, dizziness, and hypotension have also been reported in some participants of historical DSIP studies, overlapping symptoms could make it difficult to determine which substance is causing them.
A person taking tirzepatide prescribed by a doctor should discuss additional products with their treating physician instead of independently adding an unapproved peptide.
DSIP and sedatives or sleeping pills
Controlled studies have not established interactions of DSIP with:
- benzodiazepines,
- non-benzodiazepine hypnotics,
- sedating antihistamines,
- melatonin,
- with antidepressants,
- antipsychotic drugs,
- gabapentinoids,
- with other sleep-affecting products.
For some combinations, increased sleepiness, changes in concentration, altered sleep architecture, or an effect on blood pressure could theoretically occur.
However, these possibilities remain uncertain, as the clinical pharmacology and interaction profile of DSIP have not been well characterized.
DSIP and opioids
Historical studies evaluated DSIP during opioid withdrawal, and mechanistic studies suggested possible links to opioid signaling [4].
The FDA indicated that stimulation of opioid pathways could theoretically be associated with reinforcing properties or abuse potential. However, the agency did not find any relevant studies directly assessing the abuse potential of emideltide [1].
Therefore, there is no reliable basis for independently combining DSIP with opioids or medications such as methadone, buprenorphine, or naltrexone.
DSIP with other peptides
Reliable interaction studies have not established the safety of combining DSIP with substances such as Semax, Selank, Epitalon, Pinealon, growth hormone secretagogues, anabolic agents, or other experimental peptides.
The simultaneous use of multiple unapproved substances also makes it difficult to interpret adverse reactions.
If a headache, insomnia, dizziness, blood pressure change, or allergic reaction occurs, identifying the responsible substance becomes more difficult.
Does DSIP cause addiction?
DSIP has not been shown to cause addiction.
There is a lack of convincing human research data indicating DSIP-related substance craving, compulsive use, a recognized tolerance syndrome, or a clearly defined withdrawal syndrome.
However, the addictive potential has not been adequately studied.
The FDA highlighted a theoretical risk arising from data suggesting that DSIP may affect the release of endorphins or signaling associated with the opioid system. Activation of opioid pathways related to the reward system could theoretically have reinforcing properties, but the FDA has not identified relevant studies directly evaluating the addictive potential of emideltide [1].
This distinction is important.
A theoretical mechanism does not constitute proof that DSIP acts like an opioid or causes opioid-like addiction.
Similarly, anxiety and insomnia reported after the completion of treatment in individuals undergoing opioid withdrawal do not prove the occurrence of DSIP withdrawal syndrome. These symptoms could have resulted from the underlying opioid withdrawal process.
Better-controlled studies would be needed to distinguish between a relapse of the original problem and the effects of DSIP withdrawal.
Who should avoid unapproved research peptides?
Since DSIP has no approved clinical indication, established formulation, or adequately characterized safety profile, it should not be used as a method of self-treatment.
Uncertainty is particularly important in the case of specific groups.
One example is pregnancy. There is a lack of adequate studies regarding the reproductive and developmental safety of DSIP during pregnancy.
Safety during breastfeeding also remains unknown.
Children and adolescents should not receive unapproved DSIP outside of appropriately authorized trials. There is no established pediatric dose or safety standard.
Older adults may be particularly vulnerable to risks in the event of frailty, a tendency to fall, cognitive impairment, low blood pressure, or the simultaneous use of multiple medications.
Particular caution is also advised for individuals with low blood pressure, a history of fainting, cardiovascular diseases, or those taking blood pressure-lowering medications, as hypotension has been reported in historical studies of intravenous DSIP [1].
Additional uncertainty concerns individuals with severe allergies, autoimmune diseases, previous reactions to injected peptides, immunosuppression, clotting disorders, or wound healing problems.
People with sleep apnea, severe depression, bipolar disorder, psychosis, epilepsy, substance use disorders, significant kidney or liver disease, or unexplained neurological symptoms require proper medical diagnosis instead of experimental self-treatment.
It has not been established that DSIP is a safe replacement for treatments for insomnia, narcolepsy, withdrawal syndromes, or other conditions of proven efficacy.
Is DSIP approved by the FDA?
No. DSIP, emideltide in free base form, and emideltide acetate are not ingredients of any FDA-approved drug [1].
Having an FDA substance identifier or presence in a chemical database does not imply FDA approval.
In 2026, the FDA evaluated the active ingredients associated with emideltide for potential inclusion on the Section 503A list.
It was not an application for drug approval.
The FDA stated that the substances have not been sufficiently characterized, and the evidence regarding human safety and efficacy is insufficient. The agency also pointed to concerns regarding aggregation, impurities, and potential immunogenicity.
The FDA has proposed that emideltide free base and emideltide acetate not be added to the Section 503A list [1,5].
It is also important to distinguish between compounded drugs and FDA-approved drugs.
Compounded drugs do not undergo the same pre-market FDA evaluation for safety, efficacy, and manufacturing quality as approved drug products [5].
Therefore, a product does not become an FDA-approved drug just because it is prescribed by a clinic, prepared by a compounding pharmacy, or advertised as pharmaceutical grade.
The FDA also stated that it does not have sufficient information to determine whether emideltide in compounded preparations could cause harm to humans via the proposed route of administration. The agency drew special attention to potential immunogenicity and issues concerning the characterization of the peptide [8].
This is more precise than stating that the FDA „banned DSIP.” FDA approval status, compounding substance list decisions, import regulations, and enforcement actions are distinct regulatory issues.
Legal and regulatory status of DSIP
DSIP cannot simply be defined as „legal” or „illegal” in all countries.
The regulatory status depends on the country, product presentation, intended use, claimed medical properties, route of administration, supply chain, prescription requirements, and whether the product is actually supplied solely for laboratory research.
In the European Union, a product presented as intended to treat or prevent diseases, or to modify physiological functions through pharmacological, immunological, or metabolic action, may meet the legal definition of a medicinal product [9].
Medicinal products generally require an appropriate authorization before being placed on the market.
An international FDA review indicated that emideltide in the form of free base and acetate were not registered drugs in the analyzed countries and did not appear in the European, Japanese, or International Pharmacopoeias [5]. No DSIP medicinal product authorized by the EMA was identified.
A similar basic distinction applies in the UK. The MHRA regulates medicinal products, and unauthorized drugs sold online can entail both legal and health risks [10]. No MHRA-approved DSIP product has been identified.
The mere fact that a website offers DSIP shipping to the UK does not mean that the product is an approved medicine.
Searches like „DSIP zonder recept”, meaning „DSIP without a prescription”, can also be misleading.
The fact that a product is available without a prescription does not mean that it is an approved OTC drug. Approved OTC drugs have undergone the appropriate regulatory review and classification. An unapproved investigational peptide has not undergone this process.
The „research use only” label also does not have to determine the status of the product. Authentic research reagents can be legally supplied for legitimate laboratory purposes. However, the disclaimer alone may not determine the regulatory classification if the vendor simultaneously promotes the product for use in sleep, insomnia, injections, or other human applications.
Risks related to storage, degradation, and product quality
DSIP safety cannot be separated from product quality.
A contaminated, degraded, improperly concentrated, or mislabeled product may pose risks other than the pharmacological action of a properly identified DSIP.
Peptides can undergo physical and chemical changes under the influence of factors such as:
- temperature,
- moisture,
- pH,
- Oxygen,
- light,
- mixing and shaking,
- concentration,
- buffer composition,
- contact surfaces.
Possible degradation processes include oxidation, hydrolysis, isomerization, adsorption, precipitation, and aggregation [11].
The rate of these processes depends on the specific peptide and formulation. Therefore, general knowledge about peptides does not allow for determining a universal shelf life for DSIP.
Aggregation and impurities are particularly important from the perspective of immunological risk.
The FDA noted that injectable emideltide may be associated with a risk of immunogenicity due to aggregation and peptide-related impurities. There were insufficient data to rule out such a risk [1,8].
The appearance of the product alone does not allow its quality to be determined. A clear solution may still contain chemical degradation products, microorganisms, or endotoxins.
Similarly, adding bacteriostatic or sterile water does not sterilize non-sterile peptide powder or remove endotoxins.
Damaged packaging, lack of batch number information, presence of particles, turbidity, discoloration, or unverified test results may indicate product quality issues.
However, the absence of such signals does not constitute proof of safety.
Identity, concentration, purity, sterility, endotoxin level and stability are distinct quality parameters requiring appropriate testing.
How to interpret safety information about DSIP on Reddit and forums?
Reddit, internet forums, and other communities can show what users are experiencing or discussing. However, they do not make it possible to determine how often a given DSIP side effect occurs or whether it was actually caused by DSIP.
For example, a person reporting a headache after using DSIP may have actually experienced a reaction.
However, a headache can also result from sleep deprivation, dehydration, another medication, alcohol, anxiety, product contamination, an incorrect concentration, a placebo or nocebo effect, or an unrelated illness.
Products discussed on the internet may also differ significantly in their chemical form, purity, concentration, storage conditions, and route of administration.
Some users may refer to various substances as „DSIP”. Others may fail to mention concurrently used substances or make calculation errors.
Online communities are also susceptible to selection bias. Individuals experiencing exceptionally strong positive or negative effects may be more likely to publish their experiences than those who noticed no effect at all.
When evaluating such a report, it is worth paying attention to whether the product has been independently tested, what route of administration was used, whether other medications or alcohol were used at the same time, whether the person had pre-existing health conditions or sleep problems, and whether the symptoms disappeared after discontinuing the product.
Even a very detailed account remains an anecdote, however, rather than a controlled clinical trial.
Serious symptoms should not be addressed with advice from a forum. Difficulty breathing, swelling of the face or throat, fainting, severe or persistent hypotension, chest pain, confusion, seizures, high fever, spreading redness around the injection site, or a rapidly deteriorating condition require urgent medical evaluation.
What do current evidence show, and what do they not confirm?
| Question | Evidence-based response |
|---|---|
| Are the side effects of DSIP known? | In historical intravenous studies, several transient adverse events have been reported, but their overall frequency and full profile remain unknown. |
| Was DSIP well tolerated in insomnia studies? | In some very small and short intravenous studies, few significant adverse events were reported, but this does not allow for the establishment of general or long-term safety. |
| Has the safety of subcutaneous DSIP been confirmed? | No. The FDA did not find clinical safety data regarding the proposed subcutaneous route. |
| Has the safety of the DSIP nasal spray been confirmed? | No. There is a lack of adequate human clinical data regarding the safety of this route of administration. |
| Can DSIP make sleep worse? | Short-term excitation and inconsistent effects on sleep have been reported, but insomnia has not been established as a common adverse effect. |
| Does DSIP interact with alcohol or tirzepatide? | Direct interaction studies have not confirmed the safety of such combinations. The lack of data should not be interpreted as confirmation of compatibility. |
| Does DSIP cause addiction? | No dependence was demonstrated, but the addictive potential has not been adequately studied. |
| Is DSIP approved by the FDA? | No. Emideltide is not an ingredient of any FDA-approved medication. |
| Does online availability confirm legality or quality? | No. Regulatory authorization, supply lawfulness, and production quality are separate issues. |
DSIP safety data limitations
The biggest limitation of DSIP safety research is the quality and age of the available data.
Most human studies were conducted decades ago and involved small groups of participants. Adverse event reporting was usually less detailed than would be expected in a modern clinical development program.
Some important safety data also come from open-label studies on withdrawal syndrome. Symptoms of alcohol or opioid withdrawal largely overlap with potential adverse effects of DSIP, making it difficult to determine causality.
Another significant limitation is the routes of administration.
Historical human research primarily utilized supervised intravenous administration of DSIP. Contemporary online discussions more frequently involve subcutaneous injections or nasal preparations. These routes cannot automatically be considered equivalent.
There is a lack of adequate long-term randomized safety studies, contemporary dose-ranging studies, comprehensive pharmacokinetic studies, reproductive studies, pediatric studies, formal interaction studies, and a reliable post-marketing surveillance system.
Additional uncertainty is caused by product variability, as modern preparations described as „research grade” or compounded may not be chemically or microbiologically equivalent to the materials used in historical studies.
Regulatory applications may also change. The status described here reflects official information available up to August 2026, including the 2026 FDA assessment. If the current regulatory status is important, current information from the FDA, EMA, MHRA, and relevant national regulatory authorities should be checked.
Frequently asked questions about DSIP safety
What side effects of DSIP are best documented?
In historical intravenous studies, transient headaches, nausea, dizziness, sweating, and a few cases of low blood pressure were reported. This mainly involved individuals undergoing alcohol or opioid withdrawal [1,4].
Since withdrawal symptoms and formulation issues could also contribute to these symptoms, the exact causal relationship with DSIP remains uncertain.
Is the DSIP peptide safe?
Currently, DSIP cannot be classified as a substance with confirmed safety.
Small, short-term studies sometimes indicated good tolerability, but they were not large or long enough to detect rare reactions, long-term toxicity, effects on reproduction, immune responses, or important drug interactions.
The FDA stated that it does not have sufficient information to determine whether emideltide in compounded preparations could cause harm via the proposed route of administration [8].
Can DSIP cause insomnia?
Insomnia has not been established as a common side effect of DSIP. However, short-term initial agitation and inconsistent effects on sleep have been reported [1,2].
Worsening of sleep after DSIP administration can have many potential causes, so persistent insomnia requires appropriate clinical evaluation.
Can DSIP cause headache or fatigue?
Headache was reported in historical studies involving individuals undergoing withdrawal syndrome [1,4].
Fatigue has not been established as a recurrent, specific adverse effect of DSIP. It may also be caused by insufficient sleep, another medication, an underlying medical condition, or other factors.
Can DSIP cause an allergic reaction?
There is a lack of reliable data regarding the frequency of such reactions.
The FDA has pointed out potential immunogenicity issues with peptide products, particularly injection preparations, in which aggregates or impurities may be present [1,8].
Difficulty breathing, swelling of the face or throat, widespread hives, or fainting require urgent medical attention.
Does DSIP interact with alcohol?
There are no controlled studies confirming that DSIP and alcohol can be safely used simultaneously.
Studies on alcohol withdrawal do not demonstrate the safety of concurrent exposure to alcohol and DSIP. Since alcohol affects sleep, coordination, and blood pressure, combining it with a poorly characterized peptide introduces additional uncertainty.
Does DSIP interact with tirzepatide?
No direct interaction study between DSIP and tirzepatide has been conducted to confirm safety or a specific interaction.
Tirzepatide has known effects on the digestive system and metabolism, whereas the pharmacology and interaction profile of DSIP remain poorly characterized [7]. Individuals taking tirzepatide should discuss additional substances with their attending physician.
Does DSIP cause addiction or withdrawal symptoms?
No addiction syndrome or withdrawal syndrome associated with DSIP has been identified.
However, the FDA stated that the addiction potential has not been adequately studied and pointed to theoretical concerns related to opioid signaling [1].
Is DSIP FDA-approved for the treatment of insomnia?
No.
DSIP, or emideltide, is not FDA-approved for the treatment of insomnia, narcolepsy, withdrawal syndromes, or any other medical indications.
The FDA's review of emideltide in the context of the Section 503A bulks list was a separate regulatory process and did not constitute a drug approval application [1,5].
Is DSIP approved by the EMA or MHRA?
No medicinal product named DSIP approved by the EMA or MHRA was identified in the analyzed data.
Regulatory status is subject to change. If up-to-date information regarding marketing authorization is needed, official medicinal product databases should be consulted.
Is DSIP available without a prescription?
Internet availability does not mean that DSIP is an approved over-the-counter medicine.
In Europe and the UK, the way a substance is presented, advertised, and supplied can influence whether it is subject to medicinal product regulations [9,10]. The label „research use only” does not automatically make the use of a product by consumers for medical purposes lawful.
Is a certificate of analysis sufficient to confirm the safety of DSIP?
No.
An authentic batch-specific certificate can provide useful information about identity or chemical purity. However, it does not automatically confirm the correct vial content, sterility, endotoxin level, stability, clinical safety, or suitability for injection.
Who should avoid DSIP?
Since DSIP is unapproved and insufficiently researched, it should not be used for self-treatment.
Uncertainty is particularly relevant during pregnancy and breastfeeding, in children and adolescents, and in individuals with low blood pressure, cardiovascular diseases, severe allergies, immune disorders, substance use disorders, complex pharmacotherapy regimens, or significant neurological diseases and sleep disorders.
Disclaimer
The content is for educational and scientific-information purposes only. It does not constitute medical advice, diagnosis, treatment or dosage recommendations, or a recommendation for the use of DSIP.
Delta sleep-inducing peptide (DSIP/emideltide) is not approved by the U.S. FDA, the European Medicines Agency (EMA), or the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of insomnia, withdrawal syndromes, or other uses discussed in this article. The available data are limited and include small historical human studies, animal studies, and mechanistic studies.
The article does not recommend purchasing, preparing, dosing, injecting, or otherwise using DSIP. To determine current legal and regulatory requirements, information from the appropriate regulatory authority or consultation with a properly qualified legal professional should be used.
References
[1] U.S. Food and Drug Administration. (2026). Evaluation of emideltide-related bulk drug substances: Emideltide (free base) and emideltide acetate for inclusion on the 503A Bulk Drug Substances List. Pharmacy Compounding Advisory Committee briefing document. https://www.fda.gov/media/193344/download
[2] Schneider-Helmert, D., & Schoenenberger, G. A. (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 37(9), 913–917. https://doi.org/10.1007/BF01971753
[3] Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/
[4] Dick, P., Costa, C., Fayolle, K., Grandjean, M. E., Khoshbeen, A., & Tissot, R. (1984). DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology, 23(5), 364–371. https://doi.org/10.1159/000115715
[5] U.S. Food and Drug Administration. (2026). Pharmacy Compounding Advisory Committee meeting: Emideltide-related bulk drug substances. https://www.fda.gov/media/193774/download
[6] Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://pubmed.ncbi.nlm.nih.gov/1299794/
[7] U.S. Food and Drug Administration. (2026). Mounjaro (tirzepatide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf
[8] U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[9] European Commission. (2025). Auxiliary medicinal products in clinical trials. https://health.ec.europa.eu/document/download/1bf35e45-134c-4f2e-9c68-0e8537eef867_en
[10] Medicines and Healthcare products Regulatory Agency. (2026). Report a suspicious online seller of medicines or medical devices. https://report-or-check-suspicious-activity.mhra.gov.uk/report
[11] Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). Stability of protein pharmaceuticals: An update. Pharmaceutical Research, 27(4), 544–575. https://doi.org/10.1007/s11095-009-0045-6